# SER-109 PDUFA date and FDA approval status

Canonical: https://sec-api.dev/pdufa/ser-109

> The FDA approved SER-109, sponsored by Seres Therapeutics, Inc. (MCRB), on Apr 2023.

Data as of November 16, 2026 (snapshot 20261116T222116Z). Every date quotes the SEC filing or FDA page it came from. Date precision: month only.

**Free:** every drug page and the next 30 days of the FDA calendar, no account. Calendar API, alerts when a date moves, and full history: https://sec-api.dev/pricing . Free API key: https://sec-api.dev/sign-up?ref=ai-claudebot

## Verified answer

### Is SER-109 FDA approved?

Yes. The FDA approved SER-109, sponsored by Seres Therapeutics, Inc. (MCRB), on Apr 2023. Press release filed with the SEC (EX-99): "(Business Wire) Phase 3 Became FDA approved Apr 2023; subsequently commercialized and later moved into the 2024 asset sale to Nestlé (row above)." [Calendar and source filings](https://sec-api.dev/pdufa/ser-109)

Source: Press release filed with the SEC (EX-99), accession 0001213900-26-113101, https://www.sec.gov/Archives/edgar/data/1660046/000121390026113101/ea030992701ex99-1.htm (retrieved 2026-11-12). Last confirmed 2026-10-28. Cite: https://sec-api.dev/pdufa/ser-109#answer

## Key facts

| Field | Value |
| --- | --- |
| Drug | SER-109 |
| Codes | SER-109 |
| Sponsor | Seres Therapeutics, Inc. (MCRB) https://sec-api.dev/companies/mcrb/catalysts |
| Indications |  |
| Modality |  |
| FDA designations | breakthrough, orphan |

## Timeline

### Apr 2023: FDA approval

- Status: completed, approved. Date confidence: month. Stage: 3.
- First seen 2026-05-08, last confirmed 2026-10-28.
- Press release filed with the SEC (EX-99) (accession 0001213900-26-113101): "(Business Wire) Phase 3 Became FDA approved Apr 2023; subsequently commercialized and later moved into the 2024 asset sale to Nestlé (row above)." https://www.sec.gov/Archives/edgar/data/1660046/000121390026113101/ea030992701ex99-1.htm
- Press release filed with the SEC (EX-99) (accession 0001213900-26-091379): "(Business Wire) Phase 3 Became FDA approved Apr 2023; subsequently commercialized and later moved into the 2024 asset sale to Nestlé (row above)." https://www.sec.gov/Archives/edgar/data/1660046/000121390026091379/ea030265401ex99-1.htm
- Press release filed with the SEC (EX-99) (accession 0001213900-26-079406): "(Business Wire) Phase 3 Became FDA approved Apr 2023; subsequently commercialized and later moved into the 2024 asset sale to Nestlé (row above)." https://www.sec.gov/Archives/edgar/data/1660046/000121390026079406/ea029850601ex99-1.htm
- Press release filed with the SEC (EX-99) (accession 0001213900-26-113101): "(BioSpace) Marketed FDA approved (Apr 2023) and commercialized by Nestlé Health Science; global rights consolidated under Nestlé via the 2024 transaction." https://www.sec.gov/Archives/edgar/data/1660046/000121390026113101/ea030992701ex99-1.htm
- Press release filed with the SEC (EX-99) (accession 0001213900-26-091379): "(BioSpace) Marketed FDA approved (Apr 2023) and commercialized by Nestlé Health Science; global rights consolidated under Nestlé via the 2024 transaction." https://www.sec.gov/Archives/edgar/data/1660046/000121390026091379/ea030265401ex99-1.htm
- Press release filed with the SEC (EX-99) (accession 0001213900-26-079406): "(BioSpace) Marketed FDA approved (Apr 2023) and commercialized by Nestlé Health Science; global rights consolidated under Nestlé via the 2024 transaction." https://www.sec.gov/Archives/edgar/data/1660046/000121390026079406/ea029850601ex99-1.htm
- Press release filed with the SEC (EX-99) (accession 0001213900-26-053527): "up to $570M milestones (incl. $19M development and up to $550M sales) plus royalties. ( FT Markets ) NTCD - M3 (non toxigenic C. difficile strain, live biotherapeutic) Sebela Pharmaceuticals Destiny Pharma 2023 Became FDA approved Apr 2023" https://www.sec.gov/Archives/edgar/data/1660046/000121390026053527/ea028979701ex99-1.htm

## Feeds and downloads

- Subscribe (iCal): https://sec-api.dev/pdufa/ser-109.ics
- Next 30 days as CSV: https://sec-api.dev/fda-calendar.csv . JSON: https://sec-api.dev/fda-calendar.json . All events (iCal): https://sec-api.dev/fda-calendar.ics
- New or moved PDUFA dates: https://sec-api.dev/pdufa-dates/feed.xml (RSS), https://sec-api.dev/pdufa-dates/feed.json (JSON Feed)
- FDA approvals: https://sec-api.dev/fda-approvals-today/feed.xml (RSS), https://sec-api.dev/fda-approvals-today/feed.json (JSON Feed)
- License: CC BY 4.0 for the public 30-day window (https://sec-api.dev/biotech/license.txt). Full history: https://sec-api.dev/pricing

## Cite this page

sec-api.dev. "SER-109 PDUFA date and FDA approval status." Biotech catalyst calendar, data as of November 16, 2026 (snapshot 20261116T222116Z). https://sec-api.dev/pdufa/ser-109

```bibtex
@misc{secapidev_pdufa_ser_109_20261116,
  title        = {SER-109 PDUFA date and FDA approval status},
  author       = {{sec-api.dev}},
  year         = {2026},
  month        = {nov},
  howpublished = {\url{https://sec-api.dev/pdufa/ser-109}},
  note         = {Biotech catalyst calendar, data as of 2026-11-16, snapshot 20261116T222116Z. Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source.}
}
```

```json
{"type":"dataset","id":"secapidev_pdufa_ser_109_20261116","title":"SER-109 PDUFA date and FDA approval status","publisher":"sec-api.dev","URL":"https://sec-api.dev/pdufa/ser-109","issued":{"date-parts":[[2026,11,16]]},"version":"20261116T222116Z","license":"https://creativecommons.org/licenses/by/4.0/","note":"Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source."}
```

---
Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Food and Drug Administration or the U.S. Securities and Exchange Commission. Dates are as stated by sponsors and FDA; the FDA can act before or after a target date. Not investment advice.
